James J. Mullen, III
Morrison & Foerster LLP
Articles
After Myriad oral argument, Supreme Court set to decide patentability of isolated human DNA molecules
USA - April 15 2013 Today, the Supreme Court of the United States heard oral argument in Association for Molecular Pathology v. Myriad Genetics, Inc. (No. 12-398) to…
Australian Federal Court upholds Myriad’s gene patent
Australia, USA - February 15 2013 While the question of patentability of isolated gene sequences awaits resolution at the U.S. Supreme Court, the Australian Federal Court today upheld…
Myriad finally gets its day in (the Supreme) Court
USA - November 30 2012 The Supreme Court today granted certiorari in Assoc. for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al. (Myriad), to address the issue of whether human genes are patentable.
Judges don’t budge in Myriad: Federal Circuit again finds isolated gene sequences are patent-eligible subject matter
USA - August 16 2012 The Federal Circuit today issued its opinion in Assoc. for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al. (“Myriad”), in which it re-affirmed its prior ruling, despite the Supreme Court’s instruction to revisit that ruling in light of its decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc., ___U.S.___ (March 20, 2012) (“Prometheus”).
USPTO releases proposed first-inventor-to-file rules and examiner guidelines
USA - July 27 2012 Implementation of the “first-to-file” provisions of the Leahy-Smith America Invents Act (AIA) took a step forward yesterday when the United States Patent and Trademark Office (USPTO) published proposed rules and proposed examination guidelines for the first-inventor-to-file provision of the AIA.
